Weekly news updates are currently posted on the Internet site and sent out via e-blast to provide up-to-date information on what has been covered in the news regarding hepatitis C in the previous week. Topics include all stories related to hepatitis C as well as personal stories and events.
Week Ending 03/23/2015
‘In a group of young users of injection drugs, recent maintenance opioid agonist therapy with methadone or buprenorphine for opioid use disorders, such as heroin addiction, was associated with a lower incidence of hepatitis C virus (HCV) infection, according to a recent study . The use of injection drugs is a primary route of HCV transmission and young injection drug users (IDUs) are at the core of the HCV epidemic, so they may be an important target to reduce HCV transmission, according to researcher Judith I. Tsui, MD, MPH, of Boston University School of Medicine.’
The FDA has accepted Bristol-Myers Squibb’s resubmitted new drug application (NDA) for the approval of daclatasvir, an investigational hepatitis C virus (HCV) genotype 3 treatment for use in combination with sofosbuvir.
‘The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country’s health care system. The prediction comes from a cost-effectiveness analysis led by researchers at The University of Texas MD Anderson Cancer Center.’
‘Medivir AB (Nasdaq Stockholm: MVIR) today announced that new clinical data for the once-daily HCV protease inhibitor simeprevir have been presented at the 24th Conference of the Asian Pacific Association for the Study of the Liver (APASL) in Istanbul, Turkey. Six oral and poster presentations on three clinical studies spanning over several development programs including simeprevir in different treatment combinations, durations and populations were held.’
‘The cost of treating a chronic disease can add up, sometimes leading patients to hold off until the disease progresses. The most cost-effective way to treat a common liver condition, however, might be to face it head on.’ A new study looked at the cost-effectiveness of treating hepatitis C and found that immediate treatment even in patients with only moderately advanced disease was a cost-effective route.
‘Merck expects to discontinue the manufacturing and distribution of its inhibitor boceprevir for the treatment of hepatitis C virus by December, according to a company spokesperson. Boceprevir (Victrelis, Merck) is a prescribed medication to be used in combination with peginterferon alfa and ribavirin to treat adults with chronic HCV genotype 1 infection with compensated liver disease, including cirrhosis, who have not been treated before or who have failed previous treatment.’
‘Combination treatment with Olysio and Sovaldi was more effective in treating patients with hepatitis C-related Child’s Class A cirrhosis vs. treatment with pegylated interferon, ribavirin and Sovaldi, according to study data published in Gastroenterology.’